ClinicalTrials.gg
CompletedNCT02469545Updated Sep 7, 2018

Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment

A Phase 2 interventional study of Lactobacillus Plantarum 299v and Crystalline cellulose powder in Depression and Anxiety Disorder, sponsored by Medical University of Bialystok. Completed at 1 site in Poland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-07.

Sponsored by Medical University of Bialystok · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 95 studies in Depression with a site in Poland — 19 open to participants now, 23 under way, 8 of them phase 3. Depression · Poland.

Enrollment
62nd of 81
60 · median 200
Started
2014
with 1 other
Phase 2
14 of 95
3 open now
Registered
27th of 95
by date

Among the 95 studies in Depression with a site in Poland, this one is the 62nd largest by enrollment of the 81 interventional ones that give a count, is one of 2 that started in 2014, is one of 14 in phase 2, and was the 27th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

19 of the 95 studies in Depression with a site in Poland are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Depression with a site in Poland, or all of them as a file.
02

Study summary

The aim of the study is to determine the influence of supplementation of probiotic Lactobacillus Plantarum 299V vs. placebo of probiotic during antidepressant monotherapy with SSRI (Selective Serotonin Reuptake Inhibitor) in patients with major depression.

Read the detailed description

For period of 8 weeks patient will receive probiotic Lactobacillus Plantarum 299V or its placebo as a supplementation of regular depression treatment with SSRI (Escitalopram or Sertraline). Psychometric and biochemical parameters will be monitored and evaluated. At day one, after 3 weeks (day 21) and after 8 weeks (day 56) of the study psychometric parameters will be measured such as Hamilton Depression Rating Scale, PSS-10 Scale, SCL-90 scale. At day one and after 8 weeks (day 56) of the study cognitive functions will be measured using: CVLT- California Verbal Learning Test, RFFT Ruff Figural Fluency Test, Stroop Test, Connecting Points Test (A and B), Attention and Perceptivity Test. At day one and after 8 weeks (day 56) of the study biochemical parameters will be measured such as: morning cortisol, pro and anti-inflammatory cytokines, tryptophan and its kynurenic pathway metabolites concentrations.

03

Conditions studied

  • Depression
  • Anxiety Disorder

Keywords

  • depression
  • microbiota-gut-brain axis
  • Lactobacillus Plantarum 299v
  • probiotic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unipolar depression, with at least one depressive episode, present episode since at least 2 weeks, with Hamilton Depression Scale scoring 18 and higher with =18,9 - 29,9 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Inflammatory diseases eg. rheumatoid diseases, inflammatory bowel diseases, autoimmunological diseases
  • Metabolic diseases e.g. diabetes type I,II, obesity ()>30 kg/m2
  • Previously diagnosed other psychiatric diseases other than depression, psychoactive substances abuse, organic brain dysfunctions
  • Smokers
  • Patients after surgeries in last 3 months
  • Oncological patients
  • Patients during pregnancy or lactation
  • Drugs which might influence measured parameters (e.g. lithium, antibiotics, glucocorticosteroids, antipsychotic drugs)
  • Changes in routine blood biochemical parameters: morphology, electrolytes, (AST), Alanine Aminotransferase (ALT), creatinine, urea, C-reactive protein (CRP), thyroid-stimulating hormone (TSH).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    SSRI and probiotic

    Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).

    Drug: Lactobacillus Plantarum 299v · Drug: Escitalopram · Drug: Sertraline

  • Placebo comparator
    SSRI and placebo of probiotic

    Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).

    Drug: Crystalline cellulose powder · Drug: Escitalopram · Drug: Sertraline

Interventions

  • DrugLactiplantibacillus plantarum 299VStudies of Lactiplantibacillus plantarum 299VLactiplantibacillus plantarum 299V pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.

  • DrugCrystalline cellulose powder

    Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.

  • 5-20mg daily

  • 50-100mg daily

06

What researchers measure

Primary outcomes

  1. Evaluation of psychometric parameters - Change in Hamilton Depression Rating Scale from baseline at 3 weeks and 8 weeks of the study.

    Time frame: At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study

  2. Evaluation of psychometric parameters - Change in Perceived Stress Scale (PSS-10) from baseline at 3 weeks and 8 weeks of the study.

    Time frame: At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study

  3. Evaluation of psychometric parameters - Change in Symptom Checklist 90 Scale (SCL-90) from baseline at 3 weeks and 8 weeks of the study.

    Time frame: At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study

Secondary outcomes

  1. Cognitive functions evaluation - California Verbal Learning Test (CVLT)

    Time frame: At day one, after 8 weeks (day 56) of the study

  2. Cognitive functions evaluation - Ruff Figural Fluency Test (RFFT)

    Time frame: At day one, after 8 weeks (day 56) of the study

  3. Cognitive functions evaluation - Stroop Test (A and B)

    Time frame: At day one, after 8 weeks (day 56) of the study

  4. Cognitive functions evaluation - Connecting Points Test (A and B)

    Time frame: At day one, after 8 weeks (day 56) of the study

  5. Cognitive functions evaluation - Attention and Perceptivity Test

    Time frame: At day one, after 8 weeks (day 56) of the study

  6. Biochemical analysis - morning cortisol level

    Biochemical analysis will be based on pro-inflammatory and anti-inflammatory cytokines measurements, morning cortisol concentration, tryptophan and its kynurenic pathway metabolites measurements.

    Time frame: At day one, after 8 weeks (day 56) of the study

  7. Biochemical analysis - cytokines measurements profile

    Time frame: At day one, after 8 weeks (day 56) of the study

  8. Biochemical analysis - kynurenic pathway metabolites measurements profile

    Time frame: At day one, after 8 weeks (day 56) of the study

07

Study locations

1 site
  • Department of Psychiatry, Medical University of Bialystok
    Bialystok, Poland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2015
First posted
Jun 11, 2015
Start
Jun 2014
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Sep 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02469545
Lead sponsor
Medical University of Bialystok
Responsible party
Sponsor
First posted
Jun 11, 2015
Start date
Jun 2014
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Sep 7, 2018

Study contacts

Leszek Z Rudzki, MD Psychiatry Specialist
principal investigator · Department of Psychiatry, Medical University of Bialystok
Napoleon Waszkiewicz, MD PhD
study director · Psychiatry Department of Bialystok Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactiplantibacillus plantarum 299V

Start the discussion